Biguanides
Phase 3Small molecule
Eli LillyBiguanides is one of 117 small molecule programs targeting Acute Pancreatitis. It is currently in Phase 3.
4
Indications
4
Total Trials
0
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Biguanides
Eli LillyPhase 3
MS Contin
Merck & Co.Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
LDE225
NovartisPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Chemotherapy Agents
TakedaPreclinical
Secretin-Ferring
FerringPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pancreatic Cancer1 trial
Incretin-based Drugs and Pancreatic Cancer
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02475499·886,172 enrolled
Heart Failure1 trial
Incretin-based Drugs and the Risk of Heart Failure
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02456428·1,499,650 enrolled
Type 2 Diabetes Mellitus1 trial
Acute Pancreatitis1 trial
Incretin-based Drugs and Acute Pancreatitis
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02476760·1,417,914 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biguanides. EMBL-EBI & Wellcome Sanger Institute.
- [4]